Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma
about
Gastric cancer stem cells: a novel therapeutic targetStem cells in gastric cancerClinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved.Notch as a Driver of Gastric Epithelial Cell Proliferation.Genetic Alterations in Gastric Cancer Associated with Helicobacter pylori Infection.A new case of syringocystadenocarcinoma papilliferum: a rare pathology for a wide-ranging comprehension.RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer.Prognostic value of CD133 expression in stage I lung adenocarcinomas.Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival.Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic reviewCancer Stem Cell Markers CD44, CD133 in Primary Gastric AdenocarcinomaClinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis.Gastric cancer stem cells: evidence, potential markers, and clinical implications.CD133 overexpression correlates with clinicopathological features of gastric cancer patients and its impact on survival: a systematic review and meta-analysis.Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.Cancer stem cells and their role in metastasisβ -Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells.Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancerStudy on the Biological Characteristics of CD133 (+) Cells Interfered by RNA Interference in Gastric Cancer.Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells.Current molecular markers for gastric progenitor cells and gastric cancer stem cells.CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.Cancer stem cells in human digestive tract malignancies.Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma.Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis.Aberrant expression of CD133 and musashi-1 in preneoplastic and neoplastic human oral squamous epithelium and their correlation with clinicopathological factors.Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas.Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression in gastric cancer: a systematic review and meta-analysis.Evaluation of E-cadherin Expression in Gastric Cancer and Its Correlation with Clinicopathologic Parameters.CD133 expression: a potential prognostic marker for non-small cell lung cancers.Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer.Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.The potential therapeutic effect of melatonin on human ovarian cancer by inhibition of invasion and migration of cancer stem cells.Evaluation of METase-pemetrexed-loaded PEG-PLGA nanoparticles modified with anti-CD133-scFV for treatment of gastric carcinoma.Interaction between CD133 and PI3K-p85 promotes chemoresistance in gastric cancer cells.Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.CD133 is a marker of gland-forming cells in gastric tumors and Sox17 is involved in its regulation.associated factors in the development of gastric cancer with special reference to the early-onset subtype
P2860
Q27002840-50C91B54-26FA-4B15-A1F3-366524361F77Q27027153-35F0A04B-0C63-4B9D-8215-D65E4DBF890CQ30244324-FEF9976F-0D5D-4FF7-B8BD-A2F2BEAE4CB5Q33600442-AE0539EA-342F-40E3-A6A3-1A4EC1888125Q33621927-628AD8F4-782B-43BB-BAF1-34DD9D289FC8Q33737418-EBF826FA-E779-4B33-82ED-2AEA80ED9477Q33761825-1F3BB199-5E04-4FFF-B897-074EA09EA38BQ34467221-FBAD462D-AB0C-4D83-AF3E-2B4B1F1128D0Q34478585-DADFD745-9101-4C1C-9324-6ED4878C7964Q34484134-6E49494F-FD61-4199-8C88-1CEEA5A7FB95Q34637735-E3A2F05E-9F07-42A2-9D0F-DA90016277C1Q34948623-592785C7-8CE4-41D2-89CA-735C73C944D9Q35132045-3234DA76-8412-464B-88D6-28EE2DFD9E77Q35795934-BA772807-4485-4931-A02D-AB7E6A642243Q35822133-D4780B65-D3F1-40A1-BBFE-915E886913F3Q35987358-75619685-E4F6-464E-9F18-C70AE2F193B3Q36698757-8D237C7F-B828-4B8B-9437-4AB403F9D649Q36848635-7F2AFCBB-4F9C-48E5-B505-95F513FF53E3Q37468314-8BE39557-A68B-4DB4-B73E-6B8AA4D0353DQ37688113-17ECB6D3-C4F1-4AE7-A600-14513F3024A2Q37697615-ECD074E6-1B54-41D5-9078-A4B1783798E4Q37882566-FA5912CB-4260-472F-97D5-8420077F3611Q38035206-F2D58982-D6AB-4C1F-ADB5-1FA695AED8A2Q38162444-9F8D02A3-5090-4666-A878-0F1277726058Q38601789-039ACFE8-FCFF-4DF4-A0E6-EA0AEC8ED8B0Q39011171-D6CA61E3-8AD7-456C-8FF2-1F3FFEC7B210Q39295168-F5088D29-413F-41CF-B6DC-87A83D716D5EQ39444412-5F1EE3D9-F6D4-4A17-B9FD-2CC2D2336E10Q40695629-B922E711-44DB-4850-9A1F-927432A2200BQ41499284-F1FD7F4F-F1D9-4FB9-B61B-B1061855BE0BQ41553557-DA5D50ED-AAAB-47ED-B22D-DBD00879749BQ43533886-BA010C26-84EB-4735-9357-69F3009D9C20Q45213995-600A5BBB-6B04-4007-8849-32458649809AQ46051896-6F800819-CD24-4816-B067-69695A6374D1Q47103306-13A44C3D-18F8-4FC0-A887-3D75D6B55EA5Q48572985-B664DE3D-4926-441C-BCA2-375C607B6E0AQ49242542-82447CBE-1B5D-4285-BE81-67F28FE23B28Q50720110-94D42F97-8B44-4DB0-9440-58C79537B24BQ53288458-405EB623-6195-4AEC-BFBD-ACC003792D04Q57939042-97C17009-1A9E-4782-9E13-1BF46F8C05E2
P2860
Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@ast
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@en
Aberrant expression of CD133 p ...... ker in gastric adenocarcinoma.
@nl
type
label
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@ast
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@en
Aberrant expression of CD133 p ...... ker in gastric adenocarcinoma.
@nl
prefLabel
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@ast
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@en
Aberrant expression of CD133 p ...... ker in gastric adenocarcinoma.
@nl
P2093
P2860
P356
P1433
P1476
Aberrant expression of CD133 p ...... rker in gastric adenocarcinoma
@en
P2093
P2860
P2888
P356
10.1186/1471-2407-10-218
P407
P577
2010-05-20T00:00:00Z
P5875
P6179
1035194916